After better-than-expected earnings, analysts lowered their sales predictions for OptimizeRx.

Nov 12, 2026, 1:01 PM ETResultsRead the original at Benzinga

Neutral

OptimizeRx beat Q3 sales and profit-per-share estimates, but cut its 2026 sales forecast and reported lower sales than a year earlier. Higher adjusted profit and wider margins balance those weaker sales signs, so the report does not clearly change its outlook.

OPRX · OptimizeRx Corporation

AI read · Neutral

The AI's read

The lower sales forecast and falling sales from a year earlier point to weaker sales. The quarter's estimate beats and rising adjusted profit show stronger profit results. The two analysts kept Buy ratings but lowered their targets, adding mixed opinion rather than a clear change in business results.

Get alerts for OPRX

Follow OptimizeRx Corporation (OPRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OPRX

Free on the App Store and Google Play, or on the web.